Egrifta (Tesamorelin) Pediatric Transition to Adult Care

What Is Tesamorelin and Why Does It Matter for Young Patients?

Tesamorelin is a synthetic analog of endogenous growth hormone-releasing hormone (GHRH). Administered as a daily subcutaneous injection of 2 mg, it stimulates pituitary somatotrophs to secrete growth hormone (GH) in a pulsatile, physiologically-patterned way. The FDA approved Egrifta SV specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, based on the Phase III LIPO-010 program and its extension data published in the New England Journal of Medicine [1].

No version of tesamorelin holds FDA approval for patients under 18, let alone under 12. Despite that, GHRH-analog physiology is relevant to pediatric endocrinology because growth hormone deficiency (GHD) in childhood is common, and some research groups have explored GHRH and its analogs as diagnostic and therapeutic tools across age groups.

The GHRH Axis in Childhood

The GH-IGF-1 axis is most active during the first three years of life and again during puberty. GHRH released from the hypothalamus triggers pulsatile GH secretion, which drives hepatic IGF-1 production. IGF-1 mediates most anabolic and growth-promoting effects [2].

In children under 12, any pharmaceutical manipulation of this axis, including off-label tesamorelin, carries a different risk-benefit calculation than in HIV-positive adults. The growing skeleton, open epiphyses, and a developing insulin-sensitivity profile all change how a GHRH stimulus is processed.

Why Transition Planning Starts Early

Children who receive any GH-axis modifying therapy, whether recombinant human GH (rhGH), GHRH analogs, or IGF-1, eventually leave pediatric care. The transition period, roughly ages 16 to 25, is associated with alarming rates of treatment discontinuation. A 2016 analysis of GHD transition programs found that up to 40% of young adults with childhood-onset GHD stopped GH therapy within two years of transferring to adult care, often without a formal re-evaluation of GH status [3].

FDA Labeling and Off-Label Use in Patients Under 12

Tesamorelin's FDA labeling is explicit. The FDA-approved prescribing information for Egrifta SV states that safety and efficacy in pediatric patients have not been established [4]. The label further notes that since tesamorelin may affect GH levels and IGF-1 concentrations, use in children with open epiphyses could cause unintended linear growth or disturb normal developmental trajectories.

What Off-Label Means in Practice

Off-label prescribing is legal and sometimes clinically appropriate, but it shifts the entire evidentiary burden to the prescribing physician. For a child under 12 receiving tesamorelin:

• Informed consent must explicitly document the absence of pediatric trial data.
• Baseline and interval IGF-1 levels must be obtained, with reference ranges adjusted for age, sex, and Tanner stage.
• Bone age radiographs (left wrist X-ray) are standard of care when any GH-axis therapy is given to a growing child [5].
• An institutional review board (IRB) or ethics consultation may be appropriate if use is part of a research context.

Regulatory Field in 2025

No pediatric studies of tesamorelin have been registered on ClinicalTrials.gov as active or completed for the under-12 age group as of January 2025. The Pediatric Research Equity Act (PREA) requires sponsors to conduct pediatric studies for new drugs, but Egrifta received a waiver because HIV-associated lipodystrophy is not considered a pediatric condition for patients in this age bracket. That waiver does not mean tesamorelin is safe in children. It means it has not been tested.

GH Deficiency Diagnosis and Transition Protocols: The Evidence Base

Because tesamorelin's direct pediatric data are absent, clinicians managing any GH-axis therapy in a child under 12 must anchor their transition protocols in the broader GHD literature. The Endocrine Society's 2011 clinical practice guideline on GHD in adults, updated guidance from the Growth Hormone Research Society (GH Research Society Consensus 2019), and the American Association of Clinical Endocrinology (AACE) all provide frameworks that apply.

The Endocrine Society Position

The Endocrine Society guideline states: "We recommend retesting of GH secretory status in patients with childhood-onset GHD after completion of linear growth to determine whether GH replacement should be continued in adulthood" [6]. This recommendation carries a Grade 1, evidence level QEEE rating, meaning it is based on expert consensus rather than large randomized controlled trials, but it is universally adopted.

Re-testing is performed after Tanner stage 5 or at approximately age 18, with a minimum two-to-four week washout off any GH-stimulating agent before provocative testing. For a child who received off-label tesamorelin, the same washout logic applies because tesamorelin's half-life is roughly 26 minutes after subcutaneous injection, though downstream IGF-1 normalization may take one to three weeks [4].

GH Stimulation Testing at Transition

Two provocative tests are typically accepted for GHD confirmation in the transition period:

1. Insulin tolerance test (ITT), still considered the gold standard, targeting blood glucose <40 mg/dL with a cortisol and GH nadir sample.
2. Macimorelin (Macrilen) stimulation test, FDA-approved in 2017 as an oral GH secretagogue for adult GHD diagnosis and increasingly used at transition because it avoids insulin-induced hypoglycemia [7].

A GH peak <5.6 ng/mL on macimorelin testing or <5 ng/mL on ITT is consistent with adult GHD and would support continued GH-axis therapy in adulthood.

IGF-1 as a Monitoring Biomarker

The Journal of Clinical Endocrinology and Metabolism published reference ranges for age- and sex-adjusted IGF-1 SDS (standard deviation scores) [8]. A target IGF-1 SDS of 0 to +2 is generally considered acceptable for adults on GH replacement. In a child under 12 on off-label tesamorelin, an IGF-1 SDS persistently above +2.5 should prompt dose reduction or cessation, given concerns about insulin resistance and theoretical oncologic risk at very high sustained IGF-1 levels.

Building the Transition Plan: A Step-by-Step Clinical Framework

A structured transition for a child under 12 who received tesamorelin off-label requires coordination across multiple domains. Below is a practical framework derived from Endocrine Society guidelines, the GH Research Society's 2019 consensus statement, and AACE recommendations.

Phase 1: Early Preparation (Ages 10 to 14)

The pediatric endocrinologist should begin transition conversations no later than age 12 for any child on a GH-axis modifying agent. Key actions in this phase include:

• Document the original indication and rationale for off-label tesamorelin use in a transferable summary letter.
• Establish a baseline metabolic panel: fasting glucose, fasting insulin, HbA1c, lipid panel, and liver function tests. Tesamorelin reduced visceral adipose tissue (VAT) by approximately 18% and improved triglycerides in adult HIV patients [1], but those metabolic effects in a growing child are not validated.
• Obtain a bone age assessment and compare it to chronological age. An advanced bone age (more than two standard deviations ahead of chronological age) may indicate IGF-1 excess.
• Consult with the adult endocrinologist who will receive the patient. A joint visit before age 16 is preferred.

Phase 2: Active Transition (Ages 15 to 18)

During this phase, three clinical decisions dominate:

Stopping versus continuing tesamorelin. Because tesamorelin has no approved adult indication outside HIV lipodystrophy, a child who did not have HIV-associated lipodystrophy as the off-label rationale will need a different agent or no GH-axis therapy at all after they reach adulthood. The prescribing physician must document the medical necessity clearly.

GH-axis re-evaluation. Off tesamorelin for at least four weeks, perform a formal GH stimulation test. If GHD is confirmed, transition to FDA-approved recombinant human GH (e.g., somatropin) at adult doses, typically 0.2 to 0.4 mg/day subcutaneously, titrated to IGF-1 SDS between 0 and +2 [6].

Metabolic surveillance. Fasting glucose and insulin sensitivity should be monitored every six months. The NEJM trial of tesamorelin in adults showed a statistically significant increase in fasting glucose compared to placebo (P<0.05) over 52 weeks [1], which reinforces the need for glucose surveillance when this drug has been used in a young patient.

Phase 3: Adult Care Handover (Age 18 to 21)

The formal handover document, delivered to the adult endocrinologist, should include:

• Duration and total cumulative dose of off-label tesamorelin.
• All IGF-1 and GH stimulation test results, including dates and assay methods.
• Bone age assessments and final adult height prediction versus realized height.
• Metabolic trajectory data: body composition (DXA preferred), HbA1c trend, and lipid panel series.
• Any adverse events documented during pediatric treatment.

A verbal or electronic handover alone is insufficient. A 2020 systematic review in the British Medical Journal found that written transition summaries reduced loss to follow-up by 33% compared to verbal-only handovers in chronic pediatric disease programs [9].

Safety Monitoring During and After Off-Label Tesamorelin in Children Under 12

Three safety domains require particular attention when tesamorelin has been used off-label in this age group: oncologic surveillance, glucose metabolism, and fluid retention.

Oncologic Surveillance

IGF-1 is a mitogenic hormone. Epidemiologic data from large cohort studies suggest that sustained IGF-1 levels in the upper quintile of the population are associated with modestly increased risks of breast, prostate, and colorectal cancer in adults [10]. In children, prolonged supraphysiologic IGF-1 is theoretically more concerning because more cell divisions occur during the growth years. The FDA label for Egrifta includes a contraindication for use in patients with active malignancy and a warning about IGF-1 elevation [4].

For a child who received tesamorelin off-label, annual physical examination with attention to lymphadenopathy and organomegaly is appropriate. There is no guideline-mandated imaging protocol specific to tesamorelin in children, given the absence of pediatric trial data, but clinical vigilance is standard.

Glucose Metabolism

Tesamorelin raises GH, which is counter-regulatory to insulin. In the Phase III adult trials, tesamorelin produced a mean increase in fasting glucose of approximately 3 mg/dL versus placebo after 52 weeks, and a small but measurable increase in HbA1c [1]. Children already have more dynamic insulin sensitivity than adults, and puberty itself induces transient insulin resistance. Any child on tesamorelin should have HbA1c checked at baseline, six months, and annually thereafter.

Fluid Retention and Edema

GH stimulation causes sodium and water retention. Peripheral edema, arthralgias, and carpal tunnel syndrome are all recognized adverse effects of GH-axis excess in adults [6]. In prepubertal children, these effects may manifest differently, often as growing pains or joint discomfort. Families should be counseled to report persistent ankle swelling or hand numbness.

Communicating With Families During Transition

Parents of a child who received off-label tesamorelin face particular uncertainty during transition because the therapy sits outside established pediatric guidelines. Two principles should anchor all family communication.

First, the absence of evidence is not evidence of absence of risk. Parents should understand that tesamorelin has not been studied in children, and long-term effects on growth, metabolism, and cancer risk remain genuinely unknown.

Second, the transition to adult care is not abandonment. Research from the Society for Adolescent Health and Medicine shows adolescents with chronic conditions who receive structured transition support are 2.4 times more likely to remain engaged with specialist care at age 21 compared to those receiving standard (unstructured) transition [11].

The American Academy of Pediatrics recommends that transition planning incorporate a written care plan, patient-specific education about the condition and medications, and explicit identification of the receiving adult provider before the final pediatric visit [12]. These steps apply directly to the off-label tesamorelin patient.

Shared Decision-Making at Transition

The question of whether to continue any GH-axis therapy into adulthood is a shared decision. For a patient without confirmed adult GHD on re-testing, the answer is typically to stop. For a patient who confirms GHD, the conversation shifts to rhGH rather than tesamorelin because rhGH has a strong adult indication and decades of long-term safety data from the KIMS (Pfizer International Metabolic Database) registry, which enrolled more than 15,000 adults with GHD and tracked outcomes for up to 20 years [13].

Tesamorelin, by contrast, has post-marketing safety data only in adults with HIV lipodystrophy, a population with confounders including antiretroviral drug interactions and chronic immune activation. That data cannot be extrapolated to a young adult who received tesamorelin off-label as a child.

Practical Checklist for Clinicians

A simplified clinical checklist for managing the tesamorelin-exposed child approaching transition:

• Confirm original rationale for off-label tesamorelin use is documented.
• Obtain IGF-1 SDS at every visit; target 0 to +2 during active treatment.
• Bone age X-ray at baseline and every 12 months while on therapy.
• HbA1c and fasting glucose at baseline, six months, then annually.
• Begin transition planning at age 12 to 14; identify adult endocrinologist by age 16.
• Conduct formal GH stimulation test (ITT or macimorelin) after four-week tesamorelin washout at or after Tanner stage 5.
• If GHD confirmed, transition to FDA-approved somatropin at adult starting dose (0.2 mg/day), not tesamorelin.
• Deliver written transition summary to adult provider before final pediatric visit.
• Schedule first adult endocrinology appointment within three months of final pediatric visit.
• At 12-month adult follow-up, re-check IGF-1 SDS and metabolic panel.